Pfizer drug shows early promise in Xalkori-resistant lung cancer-study

May 13 (Reuters) - An experimental Pfizer Inc drug that aims to help lung cancer patients with specific genetic mutations who have stopped responding to the company's Xalkori was showing promise in a small, early stage study, according to preliminary data revealed on Wednesday.